Calidi Biotherapeutics Reports Q1 2025 Losses, Highlights Leadership Change and Clinical Trial Progress

Calidi Biotherapeutics, Inc. (NYSEARCA: CLDI) has reported its quarterly financial results for the period ending March 31, 2025, revealing both advancements and ongoing challenges within the company.

Key Financial Highlights:

• Net Loss: $5.062 million, showing an improvement from a net loss of $7.225 million during the same period in 2024.
• Operating Expenses: Total operating expenses of $5.062 million, down 25% from $6.752 million in Q1 2024.
• Research and Development (R&D) Expenses: Decreased to $2.425 million from $2.743 million in Q1 2024.
• General and Administrative Expenses: Reduced to $2.637 million from $4.009 million in Q1 2024, due to lower salaries, benefits, and legal expenses.
• Revenue from Grant Income: $50,000 recognized this quarter, compared to $0 in Q1 2024.
• Cash Position: $10.561 million in cash and $0.2 million in restricted cash as of March 31, 2025.
• Accumulated Deficit: Increased to $126.701 million, compared to $121.715 million at the end of 2024.
• Outstanding Warrants: Increased to 20,256,808 as of March 31, 2025.

Recent Developments:

• Management transition occurred, with Eric Poma appointed as CEO effective April 22, 2025 following Allan Camaisa’s resignation.
• Began a Phase 1b/2 clinical trial for CLD-101 targeting high-grade gliomas in early 2025.
• Secured $8.1 million in financing through various offerings, including a January public offering and a recent registered direct offering.
• The ongoing development of multiple product candidates for cancer therapies remains central to company operations.

Challenges:

• Continues to report significant net losses and high operating costs, with a substantial accumulated deficit indicating ongoing financial strain.
• Recent changes in management and potential delays in clinical trial funding raise questions about future operational stability.
• Need for additional capital remains crucial for sustaining operations and advancing product development, with considerable reliance on external funding.

Calidi Biotherapeutics is striving to establish its place within the immuno-oncology field while managing ongoing losses and the need for financing, amid a significant restructuring of its leadership team. Moving forward, the company's ability to secure further funding and successful validation of its therapies could be pivotal in overcoming current challenges.